(55 days)
No
The summary describes a standard glucose meter using amperometric biosensor technology and does not mention any AI or ML components.
No.
Explanation: The device is described as an "in vitro diagnostic use" system for measuring glucose, which implies it provides information about a patient's condition but does not directly treat or prevent a disease.
Yes
The "Intended Use / Indications for Use" section explicitly states "The MediSense Precision PCx Point of Care Management System for Blood Glucose is intended for the in vitro diagnostic use".
No
The device description explicitly states it utilizes "amperometric biosensor technology to generate a current," which indicates the presence of hardware components beyond just software.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
"The MediSense Precision PCx Point of Care Management System for Blood Glucose is intended for the in vitro diagnostic use (i.e. for external use only) for the quantitative measurement of glucose in fresh capillary whole blood."
This statement directly identifies the device as being for in vitro diagnostic use.
N/A
Intended Use / Indications for Use
The Precision PCx Point of Care Management System for Blood Glucose Testing is intended for in vitro diagnostic use (i.e. for external use only) for the quantitative measurement of glucose in fresh capillary whole blood. The Precision PCx Point of Care Management System for Blood Glucose Testing is for home (lay user) or professional use. The PCx Point of Care Management System for Blood Glucose Testing is for monitoring blood glucose concentration in patients with diabetes mellitus or other conditions.
Healthcare professionals may also use the product for the quantitative measurement of glucose in venous, arterial or neonatal whole blood, provided the sample is used within 30 minutes.
Product codes (comma separated list FDA assigned to the subject device)
LFR
Device Description
The Precision PCx Point of Care Management System for Blood Glucose Testing utilizes amperometric biosensor technology to generate a current. The size of the current is proportional to the amount of glucose present in the sample providing a quantitative measure of glucose in whole blood and control solutions.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
home (lay user) or professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
OCT 2 8 2002
Premarket Notification [510(k)] Summary (21 CFR 807.92)
| | Submitted by: Abbott Laboratories, MediSense Products
4A Crosby Drive
Bedford, Massachusetts 01730 |
|-----------------|----------------------------------------------------------------------------------------------------------|
| Device Name: | MediSense Precision PCx Point of Care Management System for Blood
Glucose Testing |
| Common Name: | Blood Glucose Testing System |
| Classification: | Glucose Test System, Class II per 21 CFR 862.1345 |
Predicate Devices:
Precision PCx Point of Care Management System for Blood Glucose Testing (K982303) that uses the MediSense blood glucose test strip cleared under K971812.
Description:
The Precision PCx Point of Care Management System for Blood Glucose Testing utilizes amperometric biosensor technology to generate a current. The size of the current is proportional to the amount of glucose present in the sample providing a quantitative measure of glucose in whole blood and control solutions.
Intended Use:
The Precision PCx Point of Care Management System for Blood Glucose Testing is intended for in vitro diagnostic use (i.e. for external use only) for the quantitative measurement of glucose in fresh capillary whole blood. The Precision PCx Point of Care Management System for Blood Glucose Testing is for home (lay user) or professional use. The PCx Point of Care Management System for Blood Glucose Testing is for monitoring blood glucose concentration in patients with diabetes mellitus or other conditions.
Healthcare professionals may also use the product for the quantitative measurement of glucose in venous, arterial or neonatal whole blood, provided the sample is used within 30 minutes.
Comparison to Predicate Device:
The changes to the Precision PCx Point of Care Management System for Blood Glucose Testing do not affect the technological characteristics or the intended use of the predicate Precision PCx Point of Care Management System (K982303) when using the test strips described in K971812.
1
Image /page/1/Picture/1 description: The image shows the seal for the Department of Health & Human Services - USA. The seal is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. In the center of the seal is an abstract design featuring three stylized human profiles facing to the right, with flowing lines beneath them.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV - 6 2002
Ms. Iris R. Gibbs Senior Regulatory Affairs Specialist Abbott Laboratories Inc. MediSense Products 4A Crosby Drive Bedford, MA 01730-1402
Re: K022941
Trade/Device Name: MediSense Precision PCx Point of Care Management System for Blood Glucose Testing Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: LFR Dated: August 30, 2002 Received: September 3, 2002
Dear Ms. Gibbs:
This SE Letter corrects SE Letter K022941 dated October 28, 2002. It corrects the Product Code to read LFR. The letter dated October 28, 2002 had the Product Code as NBW which is incorrect. The letter is now correct.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
3
INDICATIONS FOR USE
510(k) Number (if known):
:
Device Name:
MediSense Precision PCx Point of Care Management System for Blood Glucose Testing
Indications For Use:
The MediSense Precision PCx Point of Care Management System for Blood Glucose is intended for the in vitro diagnostic use (i.e. for external use only) for the quantitative measurement of glucose in fresh capillary whole blood. The MediSense Precision PCx Point of Care Management System is for home (lay user) or professional use. The PCx Point of Care Management System for Blood Glucose Testing is for monitoring blood glucose concentration in patients with diabetes mellitus or other conditions.
The product may also be used by healthcare professionals for the quantitative measurement of glucose in venous, arterial, or neonatal whole blood, provided that the sample is used within 30 minutes.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
第二次第二十六年(令)) 11月1日:11時10分 11時10分 11時10分 11時間 17時間 17時間 1970年 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1970 1
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use or Over-The-Counter Use (Per 21 CFR 801.108)
Jean Copin
(Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number ________________________________________________________________________________________________________________________________________________________________
Abbott Laboratories, Inc., MediSense Products